CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped down prior to trading on Friday . The stock had previously closed at $22.71, but opened at $21.44. CSL shares last traded at $21.27, with a volume of 46,395 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CSLLY. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Zacks Research lowered shares of CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Finally, Canaccord Genuity Group cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

CSL Stock Performance

The company has a 50-day moving average price of $19.62 and a two-hundred day moving average price of $30.61. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.